Kewaunee Scientific (KEQU) AI Stock Analysis

• Market Cap: $119.67M
• Dividend Yield: N/A
• Average Volume (3M): 8.77K
• Price to Earnings (P/E): 10.6
• Beta (1Y): 0.69
• Revenue Growth: 43.02%
• EPS Growth: -37.24%
• Country: US
• Employees: 1,006
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Furnishings, Fixtures & Appliances
• EPS (TTM): 0.82
• Shares Outstanding: 2,866,384
• 10 Day Avg. Volume: 10,539
• 30 Day Avg. Volume: 8,774
• PEG Ratio: -0.20
• Price to Book (P/B): 1.41
• Price to Sales (P/S): 0.38
• P/FCF Ratio: 7.18
• Enterprise Value/Market Cap: 1.10
• Enterprise Value/Revenue: 0.46
• Enterprise Value/Gross Profit: 1.58
• Enterprise Value/Ebitda: 4.96
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: $47.00 ▲(22.56% Upside)
• Action: Downgraded Date: 02/26/26
• Date: Action: Downgraded 02/26/26

The score is driven primarily by solid financial fundamentals (growth, improved leverage, strong ROE) tempered by weak recent free cash flow and thin net margins. Technicals are moderately positive in the near term but not fully supportive on a long-term trend basis, while valuation looks reasonable on a low P/E; corporate actions (refinancing) add incremental support.

Positive Factors

Revenue Growth

Consistent TTM revenue growth indicates expanding demand for Kewaunee’s lab furniture and project-based sales. Sustained top-line growth supports scale economics, strengthens customer relationships, and provides a platform for cross-selling adjacent products over the next several quarters.

Improved Leverage / Balance Sheet

A materially reduced debt-to-equity ratio and solid equity base lower financial risk and interest burden, improving flexibility for capital allocation. This stronger capital structure supports financing of growth, acquisitions, or buybacks without stressing liquidity.

Product Portfolio Expansion

Integrating Nu Aire extends Kewaunee’s addressable market into biosafety and critical lab equipment, enabling bundled solutions for customers. A broader product set increases cross-sell potential, stickiness with institutional clients, and long-term revenue diversification.

Negative Factors

Free Cash Flow Decline

A steep decline in free cash flow weakens the company’s ability to fund capex, working capital needs, and integration costs internally. Sustained FCF weakness would pressure liquidity, constrain reinvestment, and increase reliance on external financing.

Thin Net Margins

Low net margins limit earnings resilience against cost inflation or pricing pressure in project-driven furniture markets. With modest bottom-line buffers, adverse project mix or higher SG&A could quickly erode profitability and slow sustainable cash generation.

Integration / Execution Risk

While acquisition broadens offerings, successful integration is required to capture synergies. Execution risk—operational alignment, supply chain, and cultural fit—could delay anticipated cross-sell benefits and impose one-time costs that pressure near-term margins and cash flows.

Kewaunee Scientific Business Overview & Revenue Model

Company Description

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. It operates through two segments, Domestic and International. The company's products include steel, wood, laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. Its laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture; and laminate caseworks that are used in educational, healthcare, and industrial applications. The company sells its products primarily through dealers, its subidiaries, and a national distributor. Kewaunee Scientific Corporation was founded in 1906 and is headquartered in Statesville, North Carolina.

How the Company Makes Money

Kewaunee Scientific generates revenue through the sale of its laboratory furniture and equipment, which are sold to a diverse client base including educational institutions, hospitals, and research facilities. The company operates on a direct sales model, supplemented by distributors and representatives, allowing it to reach a broad market. Key revenue streams include custom laboratory installations, standard product sales, and ongoing maintenance and service contracts. Kewaunee also benefits from strategic partnerships with construction and design firms that integrate its products into new laboratory builds and renovations, further enhancing its market presence and revenue potential.

Kewaunee Scientific Financial Statement Overview

Summary

Strong TTM revenue growth (8.49%) and improved leverage (debt-to-equity 0.25) support the score, along with robust ROE (17.79%). Offsetting this are thin net margins (4.11%) and a sharp TTM free cash flow decline (-72.63%), which raises cash generation and durability concerns.

Income Statement

Kewaunee Scientific has demonstrated strong revenue growth with a TTM increase of 8.49%. The gross profit margin is healthy at 29.09%, indicating efficient cost management. However, the net profit margin is relatively low at 4.11%, suggesting room for improvement in profitability. The EBIT and EBITDA margins are moderate, reflecting stable operational performance.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.25 in the TTM, indicating a strong reduction in leverage. Return on equity is robust at 17.79%, showcasing effective use of equity capital. The equity ratio stands at 37.92%, reflecting a solid equity base relative to total assets.

Cash Flow

Kewaunee Scientific's free cash flow has decreased significantly by 72.63% in the TTM, which is a concern. The operating cash flow to net income ratio is 0.47, indicating moderate cash generation relative to earnings. The free cash flow to net income ratio is strong at 0.88, suggesting efficient conversion of earnings to cash.

Breakdown	TTM	Apr 2025	Apr 2024	Apr 2023	Apr 2022	Apr 2021
Income Statement
Total Revenue	285.51M	240.47M	203.75M	219.49M	168.87M	147.47M
Gross Profit	83.07M	68.86M	52.05M	35.59M	24.22M	23.99M
EBITDA	26.48M	22.76M	18.04M	8.16M	916.00K	459.00K
Net Income	11.74M	11.40M	18.75M	1.36M	-6.00M	-3.61M
Balance Sheet
Total Assets	189.07M	194.65M	134.77M	118.90M	118.77M	89.38M
Cash, Cash Equivalents and Short-Term Investments	12.59M	14.94M	23.27M	8.08M	4.43M	5.21M
Total Debt	24.02M	50.16M	11.00M	12.92M	67.56M	16.15M
Total Liabilities	117.36M	128.41M	78.56M	80.41M	82.59M	47.90M
Stockholders Equity	69.85M	64.46M	54.76M	37.41M	35.69M	41.24M
Cash Flow
Free Cash Flow	5.12M	12.62M	15.19M	-7.94M	-9.79M	-1.49M
Operating Cash Flow	8.67M	14.78M	19.56M	-3.79M	-7.88M	912.00K
Investing Cash Flow	-32.28M	-30.90M	-4.37M	-4.15M	-1.91M	-2.40M
Financing Cash Flow	7.98M	7.41M	-3.01M	14.93M	11.03M	1.98M

Kewaunee Scientific Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 38.35
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KEQU, the sentiment is Positive. The current price of 38.35 is below the 20-day moving average (MA) of 40.80, below the 50-day MA of 39.32, and below the 200-day MA of 44.52, indicating a neutral trend. The MACD of 0.69 indicates Negative momentum. The RSI at 55.97 is Neutral, neither overbought nor oversold. The STOCH value of 49.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KEQU.

Kewaunee Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FLXS	71 Outperform	$269.04M	14.05	14.28%	1.77%	6.00%	64.58%
ETD	70 Outperform	$574.32M	13.25	9.21%	7.86%	-4.26%	―
KEQU	68 Neutral	$119.67M	10.59	18.18%	―	43.02%	-37.24%
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
BSET	57 Neutral	$128.86M	21.33	4.70%	4.59%	-2.74%	―
HOFT	54 Neutral	$151.75M	-4.98	-11.27%	7.20%	-12.09%	-204.66%
VIRC	47 Neutral	$99.77M	25.08	3.37%	1.59%	-27.97%	-83.58%

Kewaunee Scientific Corporate Events

Kewaunee Scientific Sets Date for Q3 2026 Results

On February 25, 2026, Kewaunee Scientific Corporation announced it will release its third quarter fiscal 2026 financial results after the market close on March 11, 2026, with the information to be made available on its website. The timing of this announcement signals an upcoming update on the company’s operating performance, which will be closely watched by investors following its recent expansion into complementary laboratory equipment through the Nu Aire acquisition.

Kewaunee Scientific, a long-established supplier of laboratory and technical furniture with a growing global footprint, is positioning itself as a more integrated provider of lab infrastructure solutions. The addition of Nu Aire’s biological safety cabinets, CO2 incubators, and ultralow freezers broadens the company’s product ecosystem, potentially enhancing its competitive standing in both domestic and international laboratory markets ahead of the forthcoming earnings release.

The most recent analyst rating on (KEQU) stock is a Hold with a $46.00 price target. To see the full list of analyst forecasts on Kewaunee Scientific stock, see the KEQU Stock Forecast page.

Kewaunee Scientific Successfully Refinances Debt

On December 4, 2025, Kewaunee Scientific Corporation announced the successful refinancing of its debt and the full repayment of its Seller Notes, which were originally issued in connection with the acquisition of Nu Aire, Inc. This financial maneuver was facilitated by an amendment to a loan agreement with PNC Bank, allowing Kewaunee to repay the $23 million Seller Notes ahead of their 2027 maturity date. The refinancing has reduced the company’s overall debt load and interest expenses, reflecting Kewaunee’s commitment to strategic capital management and positioning it for future growth initiatives.

The most recent analyst rating on (KEQU) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Kewaunee Scientific stock, see the KEQU Stock Forecast page.

Kewaunee Scientific to Release Q2 Earnings Soon

On November 26, 2025, Kewaunee Scientific Corporation announced plans to release its second quarter fiscal 2026 earnings on December 10, 2025. This release will be available on the company’s website following the close of trading. The announcement is part of Kewaunee’s ongoing efforts to keep stakeholders informed about its financial performance and market position.

The most recent analyst rating on (KEQU) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Kewaunee Scientific stock, see the KEQU Stock Forecast page.